FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

Slides:

Advertisements

Similar presentations

The expression and signaling of FGFR3 in WM cells.

Advertisements

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

From: IGF-1 Regulates the Extracellular Level of Active MMP-2 and Promotes Müller Glial Cell Motility Invest. Ophthalmol. Vis. Sci ;56(11):

Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. A,

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

MAPK pathway inhibitors.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Luminex phosphorylation measurements are reproducible and have broad dynamic range Individual difference in insulin‐induced phosphorylation of ERK measured.

Reduction of Sca-1 increases PPARγ expression.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

NRP2 represses IGF-IR expression and signaling.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

CHK1 downregulation upon ERG overexpression.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

NF1 downregulation activates MAPK pathway signaling.

MITF upregulation leads to Hsp90i resistance

Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation. Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

Daple is required for activation of Gαi3, Rac1, and AKT signals and in the antagonistic inhibition of β-catenin–dependent Wnt signals downstream of EGF/EGFR.

The up-regulation of Galnt3 by Pi requires activation of the ERK pathway and induction of Egr1 and Etv5. The up-regulation of Galnt3 by Pi requires activation.

Susceptibility of rat AECII in primary culture to IAV infection is reduced by rapamycin (mTOR inhibitor) or BGJ398 (FGFR inhibitor). Susceptibility of.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

TNFα is an important survival and growth signal for melanoma.

Kinetics of BDNF-induced Erk, Akt and PLCγ activation in the presence of 15 mM NaCl or 15 mM KCl. Representative western blots (A) and quantitative plots.

CML-HSA treatment activates MAPK family members ERK1/2 and p38 but not JNK. Samples were taken at the indicated times after 100 μg/ml CML-HSA exposure.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

The dynamics of Akt activation in cultured human keratinocytes.

OPCML-associated RTK modulation affects downstream signaling.

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

Variation in dUTPase expression in cell lines.

Identification of NSC as a FADD-kinase inhibitor.

AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

ALDH1A3 is mainly responsible for the ALDH activity in two human cholangiocarcinoma lines. ALDH1A3 is mainly responsible for the ALDH activity in two human.

EGFR and cetuximab sensitivity of SCCUAT

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Western blot analysis of Wnt signaling genes.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

Transcriptional and genomic targets of EN1 in TNBC cells.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Gain-of-function conferred by RNF31 SNPs

Dual apoptotic signaling pathways triggered by IMMU-140: Anti–HLA-DR- and SN-38–mediated signals. Dual apoptotic signaling pathways triggered by IMMU-140:

PKCζ is tyrosine phosphorylated by EGF and contributes to EGF-induced activation of ERK in Mef cells. PKCζ is tyrosine phosphorylated by EGF and contributes.

Cell lines with aberrant expression of NRG1 are exquisitely sensitive to downregulation of ERBB3 signaling. Cell lines with aberrant expression of NRG1.

The effects of HDAC2 knockdown on cell-cycle proteins.

Changes in signal transduction pathway induced by gefitinib.

HES1-dependent activation of SRC/STAT3 pathway is mediated by transcription-independent mechanism. HES1-dependent activation of SRC/STAT3 pathway is mediated.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Tivantinib does not inhibit MET function.

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

Western blotting confirming the presence of fusion proteins in tumor lysates and showing increased signaling pathway activation in respective tumors. Western.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

Effect of bevacizumab on the proliferation of A2780 cells.

Expression and induction of HER2 and HPSE in 231BMBC cells.

AXL overexpression decreases proliferation in vitro.

Trastuzumab resistance siRNA screen identifies PPM1H.

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Effect of dexamethasone on PCDGF/GP88 mRNA and protein expressions and effect of PCDGF/GP88 on dexamethasone-induced cell death. Effect of dexamethasone.

LUBAC is essential for NF-κB activity in ABC DLBCL

Identification of the molecular regulators of FLP formation.

H3K36me3 is not essential for LEDGF and MLL target gene occupancy.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

FGFR2 amplification in gastric and colon cancer cell lines is associated with response to NVP-BGJ398. FGFR2 amplification in gastric and colon cancer cell.

Presentation transcript:

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. A, scatter plot showing the correlation between FGF19 copy number and transcript expression of FGF19, FGFR4, and β-Klotho (KLB) in liver cancer cell lines. B, effect of NVP-BGJ398 on FGFR downstream signaling as measured by FRS2 Tyr-phosphorylation and Erk1/2 activation by Western blot analysis after 40 minutes of FGFR inhibitor treatment. Expression of α-actinin indicates equal loading. C, effect of 3 different shRNAs targeting FGFR4 in JHH7 cells upon induction with doxycycline (Dox), compared with a nontargeting shRNA. FGFR4 expression and FRS2 Tyr-phosphorylation are shown in doxycycline-induced and noninduced cell lines. Western blot analysis shows α-actin as a loading control. D, effect of FGFR4 downregulation on monolayer cell proliferation assays at day 7 after cell seeding. Vito Guagnano et al. Cancer Discovery 2012;2:1118-1133 ©2012 by American Association for Cancer Research